# A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

> **NCT04705090** · PHASE2 · UNKNOWN · sponsor: **Shanghai YingLi Pharmaceutical Co. Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- PTCL

## Interventions

- **DRUG:** YY-20394 treatment

## Key facts

- **NCT ID:** NCT04705090
- **Lead sponsor:** Shanghai YingLi Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04
- **Primary completion:** 2022-12
- **Final completion:** 2023-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705090, "A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04705090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*